Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Farnesyltransferase inhibitor (L-744,832) restores TGF-β type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2

Abstract

Activated ras is known to dysregulate TGF-β signaling by altering the expression of TGF-β type II receptor (RII). It is well documented that tumor cells harboring mutant ras are more resistant to radiation than cells with wild-type ras. In this study, we hypothesized that the use of farnesyltransferase inhibitor (FTI, L-744,832) may directly restore TGF-β signaling through RII expression via ras dependent or independent pathway leading to induction of radiation sensitivity. Two pancreatic cancer cell lines, BxPC-3 and MIA PaCa-2 were used in this study. FTI inhibited farnesylation of Ras protein more significantly in MIA PaCa-2 than BxPC-3 cells. In contrast, MIA PaCa-2 cells were resistant to radiation when compared to BxPC-3 cells. BxPC-3 cells were more resistant to FTI than MIA PaCa-2 cells. In combination treatment, no significant radiosensitizing effect of FTI was observed in BxPC-3 cells at 5 or 10 μM. However, in MIA PaCa-2 cells, a significant radiosensitizing effect was observed at both 5 and 10 μM concentrations (P>0.004). The TGF-β effector gene p21waf1/cip1 was elevated in combination treatment in MIA PaCa-2 but not in BxPC-3 cells. In MIA PaCa-2 cells, FTI induced TGF-β responsive promoter activity as assessed by 3TP-luciferase activity. A further induction of luciferase activity was observed in MIA PaCa-2 cells treated with radiation and FTI. Induction of TGF-β signaling by FTI was mediated through restoration of the RII expression, as demonstrated by RT–PCR analysis. In addition, re-expression of RII by FTI was associated with a decrease in DNA methyltransferase 1 (DNMT1) levels. Thus, these findings suggest that the L-744,832 treatment restores the RII expression through inhibition of DNMT1 levels causing induction of TGF-β signaling by radiation and this forms a novel molecular mechanism of radiosensitization by FTI.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Adnane J, Bizouarn FA, Chen Z, Ohkanda J, Hamilton AD, Munoz-Antonia T, Sebti SM . 2000 Oncogene 19: 5525–5533

  • Ahmed MM, Alcock RA, Chendil D, Dey S, Das A, Venkatasubbarao K, Mohiuddin M, Sun L, Strodel WE, Freeman JW . 2002 J. Biol. Chem. 277: 2234–2246

  • Ahmed MM, Sells SF, Venkatasubbarao K, Fruitwala SM, Muthukkumar S, Harp C, Mohiuddin M, Rangnekar VM . 1997 J. Biol. Chem. 272: 33056–33061

  • Alexandrow MG, Moses HL . 1995 Cancer Res. 55: 1452–1457

  • Bae HW, Geiser AG, Kim D, Chung MT, Burmester JK, Sporn MB, Roberts AB, Kim SJ . 1995 J. Biol. Chem. 270: 29460–29468

  • Basolo F, Fiore L, Ciardiello F, Calvo S, Fontanini G, Conaldi PG, Toniolo A . 1994 Int. J. Cancer 56: 736–742

  • Bernhard EJ, Stanbridge EJ, Gupta S, Gupta AK, Soto D, Bakanauskas VJ, Cerniglia GJ, Muschel RJ, McKenna WG . 2000 Cancer Res. 60: 6597–6600

  • Bigey P, Ramchandani S, Theberge J, Araujo FD, Szyf M . 2000 Gene 242: 407–418

  • Bruyneel EA, Storme GA, Schallier DC, Van den Berge DL, Hilgard P, Mareel MM . 1993 Eur. J. Cancer 29A: 1958–1963

  • Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE . 1994 Nat. Genet. 8: 27–32

  • Calonge MJ, Massague J . 1999 J. Biol. Chem. 274: 33637–33643

  • Cui W, Fowlis D, Bryson S, Duffie E, Ireland H, Balmain A, Akhurst RJ . 1996 Cell 86: 531–542

  • el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y . 1994 Cancer Res. 54: 1169–1174

  • el-Deiry WS, Nelkin BD, Celano P, Yen RW, Falco JP, Hamilton SR, Baylin SB . 1991 Proc. Natl. Acad. Sci. USA 88: 3470–3474

  • Filmus J, Zhao J, Buick RN . 1992 Oncogene 7: 521–526

  • Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin Jr AS . 1997 J. Biol. Chem. 272: 24113–24116

  • Fralix KD, Ahmed MM, Mattingly C, Swiderski C, McGrath PC, Venkatasubbarao K, Kamada N, Mohiuddin M, Strodel WE, Freeman JW . 2000 Cancer 88: 2010–2021

  • Freeman JW, Mattingly CA, Strodel WE . 1995 J. Cell Physiol. 165: 155–163

  • Galang CK, Der CJ, Hauser CA . 1994 Oncogene 9: 2913–2921

  • Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, Neumann A, Brattain MG, Chang J, Kim SJ, Kinzler KW, Vogelstein B, Willson JK, Markowitz S . 1999 Cancer Res. 59: 320–324

  • Gupta AK, Bakanauskas VJ, Cerniglia GJ, Cheng Y, Bernhard EJ, Muschel RJ, McKenna WG . 2001 Cancer Res. 61: 4278–4282

  • Gupta AK, Bernhard EJ, Bakanauskas VJ, Wu J, Muschel RJ, McKenna WG . 2000 Radiat. Res. 154: 64–72

  • Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE . 1996 Science 271: 350–353

  • Hermens AF, Bentvelzen PA . 1992 Cancer Res. 52: 3073–3082

  • Hu YX, Watanabe H, Ohtsubo K, Yamaguchi Y, Ha A, Motoo Y, Okai T, Sawabu N . 1998 Clin. Cancer Res. 4: 1147–1152

  • Joshi-Barve SS, Rangnekar VV, Sells SF, Rangnekar VM . 1993 J. Biol. Chem. 268: 18018–18029

  • Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ . 1992 Proc. Natl. Acad. Sci. USA 89: 6403–6407

  • Kautiainen TL, Jones PA . 1986 J. Biol. Chem. 261: 1594–1598

  • Leach SD, Berger D, Davidson BS, Curley SA, Tainsky MA . 1998 Pancreas 16: 491–498

  • MacLeod AR, Rouleau J, Szyf M . 1995 J. Biol. Chem. 270: 11327–11337

  • MacLeod AR, Szyf M . 1995 J. Biol. Chem. 270: 8037–8043

  • Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B . 1995 Science 268: 1336–1338

  • Marte BM, Downward J . 1997 Trends Biochem. Sci. 22: 355–358

  • Massague J . 1990 Annu. Rev. Cell Biol. 6: 597–641

  • Miller AC, Kariko K, Myers CE, Clark EP, Samid D . 1993 Int. J. Cancer 53: 302–307

  • Nalca A, Qiu SG, El-Guendy N, Krishnan S, Rangnekar VM . 1999 J. Biol. Chem. 274: 29976–29983

  • Reiss M, Barcellos-Hoff MH . 1997 Breast Cancer Res. Treat. 45: 81–95

  • Rouleau J, MacLeod AR, Szyf M . 1995 J. Biol. Chem. 270: 1595–1601

  • Saha D, Datta PK, Beauchamp RD . 2001 J. Biol. Chem. 276: 29531–29537

  • Sells SF, Muthukumar S, Sukhatme VP, Crist SA, Rangnekar VM . 1995 Mol. Cell. Biol. 15: 682–692

  • Shichinohe T, Senmaru N, Furuuchi K, Ogiso Y, Ishikura H, Yoshiki T, Takahashi T, Kato H, Kuzumaki N . 1996 J. Surg. Res. 66: 125–130

  • Simeone DM, Pham T, Logsdon CD . 2000 Ann. Surg. 232: 73–80

  • Song SY, Meszoely IM, Coffey RJ, Pietenpol JA, Leach SD . 2000 Neoplasia 2: 261–272

  • Sporn MB, Roberts AB . 1990 Ann. NY Acad. Sci. 593: 1–6

  • Venkatasubbarao K, Ahmed MM, Mohiuddin M, Swiderski C, Lee E, Gower Jr WR, Salhab KF, McGrath P, Strodel W, Freeman JW . 2000 Anticancer Res. 20: 43–51

  • Venkatasubbarao K, Ammanamanchi S, Brattain MG, Mimari D, Freeman JW . 2001 Cancer Res. 61: 6239–6247

  • Wrana JL, Attisano L, Wieser R, Ventura F, Massague J . 1994 Nature 370: 341–347

  • Zhao J, Buick RN . 1995 Cancer Res. 55: 6181–6188

Download references

Acknowledgements

This work is supported by a grant from NCI 1 R01 CA86937, to MM Ahmed.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mansoor M Ahmed.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alcock, R., Dey, S., Chendil, D. et al. Farnesyltransferase inhibitor (L-744,832) restores TGF-β type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2. Oncogene 21, 7883–7890 (2002). https://doi.org/10.1038/sj.onc.1205948

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205948

Keywords

This article is cited by

Search

Quick links